Moberg Pharma Q3’2024: Positive sales development awaiting US news - Redeye

Redeye comments on the Q3 report from Moberg Pharma. The sales came in slightly higher than expected at SEK 3.9m vs our SEK 3.55m. Gross margins were better paired with good cost control, bringing in a better-than-anticipated EBIT. The investment in intangibles was higher than expected, affecting cash flow. We do not expect to make significant changes as the primary change item is the US phase 3, with no new news in the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/1055556/moberg-pharma-q32024-positive-sales-development-awaiting-us-news?utm_source=finwire&utm_medium=RSS